KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Adaptive Biotechnologies (ADPT) Leases (2020 - 2025)

Adaptive Biotechnologies' Leases history spans 6 years, with the latest figure at $40.6 million for Q4 2025.

  • For Q4 2025, Leases fell 11.25% year-over-year to $40.6 million; the TTM value through Dec 2025 reached $40.6 million, down 11.25%, while the annual FY2025 figure was $40.6 million, 11.25% down from the prior year.
  • Leases for Q4 2025 was $40.6 million at Adaptive Biotechnologies, down from $42.0 million in the prior quarter.
  • Across five years, Leases topped out at $92.1 million in Q2 2021 and bottomed at $40.6 million in Q4 2025.
  • The 5-year median for Leases is $76.2 million (2023), against an average of $66.8 million.
  • The largest annual shift saw Leases skyrocketed 184.96% in 2021 before it plummeted 38.18% in 2024.
  • A 5-year view of Leases shows it stood at $87.7 million in 2021, then decreased by 7.89% to $80.8 million in 2022, then tumbled by 35.5% to $52.1 million in 2023, then dropped by 12.15% to $45.8 million in 2024, then dropped by 11.25% to $40.6 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Leases are $40.6 million (Q4 2025), $42.0 million (Q3 2025), and $43.3 million (Q2 2025).